Compare CCNE & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCNE | ARVN |
|---|---|---|
| Founded | 1865 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 736.3M | 740.5M |
| IPO Year | N/A | 2018 |
| Metric | CCNE | ARVN |
|---|---|---|
| Price | $26.88 | $12.53 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 23 |
| Target Price | ★ $29.00 | $17.80 |
| AVG Volume (30 Days) | 101.9K | ★ 2.6M |
| Earning Date | 10-30-2025 | 11-05-2025 |
| Dividend Yield | ★ 2.67% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.91 | N/A |
| Revenue | $227,923,000.00 | ★ $312,300,000.00 |
| Revenue This Year | $13.84 | N/A |
| Revenue Next Year | $27.68 | N/A |
| P/E Ratio | $14.11 | ★ N/A |
| Revenue Growth | 5.27 | ★ 93.86 |
| 52 Week Low | $19.32 | $5.90 |
| 52 Week High | $28.30 | $26.78 |
| Indicator | CCNE | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 69.72 | 62.14 |
| Support Level | $25.78 | $11.66 |
| Resistance Level | $26.20 | $12.62 |
| Average True Range (ATR) | 0.63 | 0.90 |
| MACD | 0.21 | 0.04 |
| Stochastic Oscillator | 89.88 | 61.61 |
CNB Financial Corp is providing integrated financial solutions, which create value for both consumers and businesses. These solutions encompass deposit accounts, private banking, real estate, commercial, industrial, residential and consumer loans and lines of credit, credit cards, treasury services, online banking, mobile banking, merchant credit card processing, remote deposit and accounts receivable handling. It derives revenue through the operations as a full-service bank engaging in a full range of banking activities and services, including trust and wealth management services, for individual, business, governmental, and institutional customers. The company branch are located in Pennsylvania, Ohio, New York and Virginia.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.